MARKET

CANF

CANF

CAN FITE BIOPHAR
AMEX

Real-time Quotes | Nasdaq Last Sale

2.057
-0.023
-1.11%
Opening 12:22 05/17 EDT
OPEN
2.010
PREV CLOSE
2.080
HIGH
2.080
LOW
2.010
VOLUME
104.42K
TURNOVER
--
52 WEEK HIGH
4.390
52 WEEK LOW
1.510
MARKET CAP
35.36M
P/E (TTM)
-1.4108
1D
5D
1M
3M
1Y
5Y
From BZ Small Cap Event: Can-Fite CEO Highlights Typical Deal Structure That Encompasses Its Business Development Strategy: Upfront Payments For Distribution, Regulatory Milestone Payments, Royalties And Sales Milestone Payments
https://www.youtube.com/watch?v=Fy4-KfJWgdE
Benzinga · 4d ago
Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting
Check out the full agenda via Benzinga's Events page:  * the list below is limited to some of the publicly-traded companies that will be presenting · 4d ago
Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX
Today's 5 Stock Ideas (BZ Small Cap Event Edition) Benzinga is hosting another of it's famed Benzinga Global Small Cap Conferences this week!  The festivities kick off Thursday morning just after 9 a.m.
Benzinga · 4d ago
CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the company's CEO Dr. Pnina Fishman will present at Benzinga...
Benzinga · 5d ago
Adenosine Receptor A3 Market Size, Share and Forecast 2021- 2028 By Ameco Research
Comserve · 05/07 08:11
Can-Fite to Present at Benzingas Global Small Cap Conference on May 13, 2021
Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
Business Wire · 05/06 12:00
Can-Fite’s reaches 75% enrollment in late-stage psoriasis study; Top line results expected in Q4
Can-Fite BioPharma (CANF) announces that 75% of patients have been enrolled in its Phase III Comfort study designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to Apremilast
Seekingalpha · 04/29 13:02
BRIEF-Can-Fite’S Phase 3 Psoriasis Study Achieves 75% Enrollment, Results Expected Q4 2021
reuters.com · 04/29 12:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CANF. Analyze the recent business situations of CAN FITE BIOPHAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CANF stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 9
Institutional Holdings: 356.04K
% Owned: 2.07%
Shares Outstanding: 17.19M
TypeInstitutionsShares
Increased
1
33.68K
New
3
224.94K
Decreased
4
5
Sold Out
1
913
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.81%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
Chairman/Director
Ilan Cohen
Chief Executive Officer/Director
Pnina Fishman
Chief Financial Officer/Chief Operating Officer
Motti Farbstein
Director
Guy Regev
Director
Abraham Sartani
Director
Israel Shamay
No Data
  • All
  • Financials
  • Insiders
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers kinds of Can Fite Biopharma Ltd stock information, including AMEX:CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.